Kelun-Biotech Secures Breakthrough Therapy Designation for New Cancer Treatment
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has taken a significant step in the fight against lung cancer. The company has been granted Breakthrough Therapy Designation for its innovative therapy, sacituzumab tirumotecan (sac-TMT), in combination with the immunotherapy pembrolizumab. This designation was awarded by the Center for Drug Evaluation of China's National Medical Products Administration.
What is Sacituzumab Tirumotecan?
Sac-TMT is an antibody-drug conjugate that has shown promise in clinical trials for treating patients diagnosed with non-small cell lung cancer (NSCLC). It targets the TROP2 protein, which is often overexpressed in various solid tumors, including NSCLC. This targeted approach enhances the drug's ability to attack cancer cells directly, making it a valuable option for patients who test positive for PD-L1.
Significance of Breakthrough Therapy Designation
This designation is not merely a title; it signifies the potential efficacy of sac-TMT in treating patients whose cancer has progressed despite other therapies. With this status, Kelun-Biotech can expedite the review process for marketing approval, allowing patients faster access to potentially life-saving treatment. The company has also previously secured BTDs for multiple other cancers, namely triple-negative breast cancer and hormone-receptor positive breast cancer, showcasing its commitment to advancing oncology treatments.
Clinical Trial Success and Future Prospects
A pivotal Phase III trial, named OptiTROP-Lung05, yielded promising results when sac-TMT was administered alongside pembrolizumab as a first-line treatment exhibit. A significant improvement in progression-free survival rates was observed, alongside positive trends in overall survival rates, underscoring the therapy's potential impact on patient outcomes.
Ongoing and Future Studies
Currently, Kelun-Biotech is spearheading several registrational studies across China for sac-TMT, focusing on its efficacy across a range of malignancies including gastric cancer and gynecological tumors. Moreover, global studies led by MSD are evaluating sac-TMT in various combinations and settings, further establishing its role in cancer treatment.
About the Company
Kelun-Biotech, a subsidiary of Kelun Pharmaceutical, is dedicated to the research, development, and commercialization of novel therapies. The company has made strides in addressing unmet medical needs both domestically and internationally, particularly in the realm of cancer therapeutics. With over 30 innovative drug projects ongoing, Kelun-Biotech is positioned as a leading entity in the biotechnology landscape.
Commitment to Innovation
Kelun-Biotech's work in developing innovative treatments like sac-TMT is a testament to its commitment to improving cancer care. By focusing on drug conjugates and advancing cellular therapies, the company aims to transform the treatment landscape for patients with hard-to-treat cancers. The swift approval process for Breakthrough Therapy Designation is just one of the many routes through which Kelun-Biotech hopes to bring forward new options for patients in need.
Frequently Asked Questions
What is sacituzumab tirumotecan (sac-TMT)?
Sacituzumab tirumotecan is a novel antibody-drug conjugate developed by Kelun-Biotech for treating advanced solid tumors, particularly NSCLC.
What does Breakthrough Therapy Designation mean?
This designation speeds up the drug development process for therapies that may offer significant advantages over existing treatments.
Which cancers has sac-TMT been approved for?
It has received approvals for several conditions, including advanced lung cancer and triple-negative breast cancer.
How does sac-TMT work?
Sac-TMT targets TROP2 on cancer cells, delivering a potent drug directly into the cells to induce cell death.
What is Kelun-Biotech's mission?
Kelun-Biotech aims to innovate and provide effective therapies for a range of diseases, focusing extensively on unmet medical needs in cancer treatment.
